MedTrace Logo

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

NCT05536310 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-01-11

No results posted yet for this study

Summary

To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).

Conditions

  • Aortic Valve Stenosis
  • Aortic Valve Regurgitation
  • Aortic Valve Stenosis With Insufficiency
  • Constriction, Pathologic
  • Aortic Valve Disease
  • Heart Valve Diseases
  • Cardiovascular Diseases in Old Age
  • Ventricular Outflow Obstruction
  • Aortic Stenosis, Severe

Interventions

DEVICE

Transcatheter Aortic Valve Implantation (TAVI)

TAVI with the JenaValve Trilogy Heart Valve System

Sponsors & Collaborators

  • JenaValve Technology, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephan Baldus, MD · University Hospital of Cologne Heart Center

  • Hendrik Treede, MD · Johannes Gutenberg University Mainz

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2023-10-31
Completion
2027-10-31
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536310 on ClinicalTrials.gov